EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials

Patrice Nordmann, Ryan K Shields, Yohei Doi, Miki Takemura, Roger Echols, Yuko Matsunaga, Yoshinori Yamano

Microbial Drug Resistance · 01.04.2022 · 28 (4) · 398-407

DOI: 10.1089/mdr.2021.0180 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Microbial Drug Resistance, online erschienen am 18.04.2022. Verfasst von Patrice Nordmann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Molecular Microbiology, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cephalosporins. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study was to characterize isolates with reduced susceptibility to cefiderocol in patients receiving cefiderocol for nosocomial pneumonia or carbapenem-resistant infections in the Phase 3 APEKS-NP and CREDIBLE-CR studies. Susceptibility testing of isolates was conducted at a central laboratory, and post-treatment changes were evaluated according to available breakpoints for cefiderocol. Whole-genome sequencing and multilocus sequence typing were performed for isolates to confirm their origin and identify mutations. Five (APEKS-NP) and nine (CREDIBLE-CR) isolates demonstrated a ≥ 4-fold minimum inhibitory concentration (MIC) increase compared with genetically related baseline isolates; most remained susceptible to cefiderocol despite the ≥4-fold MIC increase. Mutations in β-lactamases or penicillin-binding protein (PBP) were identified in 4/14 isolates: one Enterobacter cloacae (amino acid [AA] substitution [A313P] in ACT-17); two Acinetobacter baumannii (one PBP3 AA substitution [H370Y], one with OXA-23 substitutions [N85I and P225S]); and one Pseudomonas aeruginosa (PDC-30 [4AA deletion “TPMA” position 316–319]). Cloning experiments using isogenic Escherichia coli strains containing wild-type and those mutant cephalosporinase enzymes show that the mutant enzymes may contribute to decreased susceptibility to cefiderocol. Pharmacokinetic data were available for nine patients, for whom cefiderocol exposures exceeded 100% f T > 4 × MIC . No clear pattern between mutations and development or extent of MIC increases was observed. No mutations were identified in genes related to iron transport, including fiu , cirA , piuA/C , and pirA , among recovered Gram-negative isolates. Clinicaltrials.gov: APEKS-NP: NCT03032380; CREDIBLE-CR: NCT02714595.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCephalosporinsCarbapenemsEscherichia coliHumansMicrobial Sensitivity TestsCefiderocol

Stichwörter der Autor:innen

MIC increasecefiderocolmutationresistancesusceptibilitywhole-genome sequencing

Substanzen

Anti-Bacterial AgentsCarbapenemsCephalosporinsCefiderocol

Autor:innen und Institutionen

  • Medical and Molecular Microbiology, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  • Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan.
  • Infectious Disease Drug Development Consulting, LLC, Easton, Connecticut, USA.
  • Shionogi, Inc., Florham Park, New Jersey, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Nordmann, P., Shields, R. K., Doi, Y., Takemura, M., Echols, R., Matsunaga, Y., & Yamano, Y. (2022). Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials. Microbial Drug Resistance, 28(4), 398-407. https://doi.org/10.1089/mdr.2021.0180

Vancouver

Nordmann P, Shields RK, Doi Y, Takemura M, Echols R, Matsunaga Y, et al. Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials. Microbial Drug Resistance. 2022;28(4):398-407. doi:10.1089/mdr.2021.0180

BibTeX
@article{Nordmann2022,
  author = {Nordmann, Patrice and Shields, Ryan K and Doi, Yohei and Takemura, Miki and Echols, Roger and Matsunaga, Yuko and Yamano, Yoshinori},
  title = {Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials},
  journal = {Microbial Drug Resistance},
  year = {2022},
  volume = {28},
  number = {4},
  pages = {398--407},
  doi = {10.1089/mdr.2021.0180}
}
Kostenlos starten →